Effect of Vitamin D Adjuvant and Allergen Specific Immunotherapy on Serum IL-10 and IL-17 Levels in Childhood Asthma: A Controlled Clinical Trial

2021 ◽  
Vol 30 (1) ◽  
pp. 175-181
Author(s):  
Lobna A. El-Korashi ◽  
Ola E. Nafea ◽  
Lamiaa G. Zake ◽  
Faika Arab ◽  
Reham H. Anis
Keyword(s):  
Childhood Asthma ◽  
Specific Immunotherapy ◽  
Pediatric Asthma ◽  
Serum Levels ◽  
Atopic Asthma ◽  
Subcutaneous Immunotherapy ◽  
Controlled Clinical Trial ◽  
Inhaled Corticosteroid ◽  
Allergen Specific Immunotherapy ◽  
Few Data

Background: 1, 25-dihydroxy vitamin D3 (VitD3) can improve the effect of allergenspecific immunotherapy (SIT). Few data is available about its role in childhood asthma. Objective: To assess the immunological and clinical efficacy of VitD3 as an adjuvant to allergen specific immunotherapy in pediatric asthma. Methodology: Sixty nine children with atopic asthma were divided into three groups: a group received subcutaneous immunotherapy (SCIT) in combination with VitD3 (n=23), another group received SCIT alone (n=23), and the last group VitD3 alone (n=23). All children were assessed at baseline, and six months for rate of inhaled corticosteroid (ICS) discontinuation, and serum levels of IL-10, and IL-17A. Results: In the SCIT + vitD3, ICS discontinuation rate was higher compared to VitD3 alone group and SCIT alone group at the end of 6th month (P=0.555 and 0.016 respectively). The combined SCIT+ VitD3 group showed significant increase of serum IL-10 level in comparison to SCIT alone group and VitD3 alone group (P=0.000) and significant decrease in serum IL-17A level compared to VitD3 alone group (P= 0.011) Conclusion: VitD3 enhance the clinical and immunological outcomes of SIT in pediatric asthma. Further investigation is needed to evaluate this effect in a larger scale to confirm its role as an adjunct to SIT.

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

2017 ◽  
Vol 131 (11) ◽  
pp. 997-1001 ◽  
Author(s):  
E Sahin ◽  
D Dizdar ◽  
M E Dinc ◽  
A A Cirik
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Long Term Effects ◽  
Allergen Specific Immunotherapy ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.

scholarly journals Allergen-Specific Immunotherapy in the Treatment of Pediatric Asthma: A Systematic Review

PEDIATRICS ◽  
2018 ◽  
Vol 141 (5) ◽  
pp. e20173833 ◽  
Author(s):  
Jessica L. Rice ◽  
Gregory B. Diette ◽  
Catalina Suarez-Cuervo ◽  
Emily P. Brigham ◽  
Sandra Y. Lin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Specific Immunotherapy ◽  
Pediatric Asthma ◽  
Allergen Specific Immunotherapy

scholarly journals A comparison of different methods of the allergen-specific immunotherapy in patients with pollinosis: the results of open randomized study

2019 ◽  
Vol 16 (3) ◽  
pp. 35-45
Author(s):  
A Y Nasunova ◽  
N M Nenasheva
Keyword(s):  
Pollen Season ◽  
Specific Immunotherapy ◽  
Allergic Rhinoconjunctivitis ◽  
Nasal Lavage ◽  
Subcutaneous Immunotherapy ◽  
Immune Reactivity ◽  
Allergen Specific Immunotherapy ◽  
New Findings ◽  
Study Results ◽  
Specific Igg4

Background. Allergen-specific immunotherapy (ASIT) is viewed as the only treatment that influences all patho-genetically significant parts of the allergic process in the initial and late phases of the IgE-mediated allergic reaction and modifies the abnormal immune reactivity to a specific allergen. Currently, sublingual (SLIT) and subcutaneous (SCIT) immunotherapy are most commonly used in clinical practice. Despite long experience of sublingual and subcutaneous immunotherapy application, questions remain about the preferred ASIT method and comparative effectiveness of different ASIT methods. This article evaluates the efficacy, benefits of SCIT and SLIT and highlights new findings related mechanisms and potential biomarkers. The aim of the study. To evaluate the comparative efficacy of different methods of ASIT (subcutaneous and sublingual) based on clinical data and biomarkers in the blood serum and other biological fluids in adult patients with allergic rhinoconjunctivitis (with/without asthma). Materials and methods. 60 patients with allergic rhinoconjunctivitis (with/without asthma) aged 18 to 50 were randomly assigned to 3 groups treated by sublingual immunotherapy with extracts of allergens, subcutaneous immunotherapy with extracts of allergens and subcutaneous with modified allergens (allergoids) respectively. Results. The efficiency of the first course of preseason ASIT (SCIT and SLIT) with extracts of allergens and aller-goids in the control of symptoms of allergic rhinoconjunctivitis (with/without asthma) was demonstrated. After the end of the first year pre-season ASIT data analysis scales (Total Symptom Score -TSS, Medircation Score -MS) revealed the best performance in the group of patients receiving SCIT with allergoids compared with patients receiving the SLIT with extracts of allergens: the scales of the TSS (p=0.023), MS (p=0.002). In addition, at the end of the maintenance phase of ASIT in patients treated with SCIT with allergoids the level of eosinophilic cationic protein (ECP) in the nasal lavage decreased by 22% (p=0.012), secretory immunoglobulin A (sIgA) in the nasal lavage increased by 70% (p=0.001), interleukin-10 (IL-10) in serum increased by 126% (p=0.006), allergen-specific IgG4 increased by 42% (p=0.01) from the initial values, that correlates with a decrease in the severity of clinical manifestations. In pollen season ECP level in nasal lavage was significantly (p=0.007) lower in a group of patients who received SCIT with allergoids compared with patients who received the SLIT with extracts of allergens. The most significant changes of serum level of IL-10 in the pollen season occurred in a group of patients receiving SCIT with allergoids compared with patients who received SLIT (p=0.013) and SCIT (p=0.001) with extracts of allergens. Conclusion. The study results deepen the existing understanding of the mechanisms of SCIT and SLIT. They allow to develop a comprehensive assessment of the therapy efficacy scheme based on clinical parameters and on monitoring of local (ECP, sIgA) and systemic biomarkers (IL-10, allergen-specific IgG4) as well.

Estimation of the efficiency of allergen-specific immunotherapy in patients with atopic asthma and allergic rhinitis

2019 ◽  
Vol 17 (6 (part 1)) ◽  
pp. 44-48
Author(s):  
O. V. Skorokhodkina ◽  
◽  
A. V. Luntsov ◽  
S. A. Arkhipova ◽  
◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Specific Immunotherapy ◽  
Atopic Asthma ◽  
Allergen Specific Immunotherapy

scholarly journals Role of periostin in evaluating the responsiveness of allergic patients to allergen-specific immunotherapy

2022 ◽  
Vol 21 (1) ◽  
pp. 184-190
Author(s):  
Nashwa M Selim ◽  
Somia El Sheikh ◽  
Wafaa S Metwally
Keyword(s):  
Specific Immunotherapy ◽  
Medical Science ◽  
Serum Levels ◽  
Total Serum ◽  
Serum Samples ◽  
Allergen Specific Immunotherapy ◽  
Prick Test ◽  
Symptom Scores ◽  
Before And After ◽  
One Year

Objectives: Allergen-specific immunotherapy (AIT) has been considered the most effective treatment for IgE mediated allergies, especially respiratory allergies. Several biomarkers have been developed to evaluate the clinical efficacy of AIT, yet none of them have been thoroughly validated. So our objective here is to investigate the usefulness of periostin as a biomaker for monitoring the efficacy of allergen immunotherapy. Materials and methods: This study included 46 healthy non-atopic volunteers and 46 patients with allergic rhinitis (AR). They were sensitized only to date palm pollen. The participants were tested by skin prick test and total serum IgE levels were measured. Serum samples were collected from healthy subjects and allergic patients before and after the one-year AIT. Serum levels of periostin, eotaxin, and sIL-2R were estimated by ELISA. Symptom scores in the allergic patients were also evaluated before and after completing one year AIT. Results: There is a significant increase in serum levels of IgE, periostin, sIL-2R, and eotaxin in allergic patients as compared to healthy controls. Symptom scores, sIL-2R and serum periostin levels were significantly decreased after one-year AIT in AR patients. Conclusion: Periostin can be used as a biomarker to evaluate AIT efficacy in AR patients. Bangladesh Journal of Medical Science Vol. 21(1) 2022 Page : 184-190

scholarly journals Modern methods of allergen-specific immunotherapy in allergic rhinitis treatment

2016 ◽  
Vol 97 (2) ◽  
pp. 288-294
Author(s):  
N M Rakhmatullina ◽  
Yu V Pastushenko ◽  
O R Trofimova ◽  
N A Sibgatullina ◽  
D G Akhmedzyanova ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Disease ◽  
Specific Immunotherapy ◽  
Immunological Response ◽  
Allergic Diseases ◽  
Repeated Administration ◽  
Pathological Process ◽  
Atopic Asthma ◽  
Allergen Specific Immunotherapy ◽  
Modern Methods

The article presents the modern methods of allergen-specific immunotherapy in patients with allergic rhinitis. Allergen-specific immunotherapy - a method of treating allergic diseases, involves reducing the organism’s sensitivity to the allergen effects by repeated administration of allergen extract, starting with the minimum dose. Given the allergic rhinitis high prevalence, as well as its tendency to increase, strong interest in effective methods of its treatment is fully justified. Over the last 20 years, it has become clear that asthma and rhinitis are two types of manifestations of a single pathological process in the airways. It has been proven that allergic disease clinical features may change over time. In addition, patients with allergy are prone to multivalent sensitization. Currently none of the drugs used to relieve allergic rhinitis symptoms can not change the organism’s response to an allergen. Allergen-specific immunotherapy can reduce allergic disease symptoms severity, reduces the need in drugs use, decreases the chance of additional sensitization to other allergens, prevents the asthma development. This therapy has become one of the most widely used effective methods of atopic diseases treatment: seasonal and perennial rhinoconjunctivitis, atopic asthma. Allergen-specific immunotherapy can lead to a change in the immunological response to the relevant allergens in early stages, acting through regulatory cells. Current studies are aimed, on the one hand, at reducing the therapeutic allergovaccines ability to cause allergic reactions, on the other - to maintain or enhance their immunogenic properties. Achieving this goal is possible by changing the route of administration and delivery of therapeutic allergens (non-injection methods of allergen-specific immunotherapy), and using a variety of allergens modification techniques.

scholarly journals The peculiarities of cytokine status in children suffering from persistent allergic rhinitis during early stages of allergenspecific immunotherapy

2009 ◽  
Vol 7 (5) ◽  
pp. 38-42
Author(s):  
E B Belan ◽  
T L Sadchikova ◽  
Uy V Antonov
Keyword(s):  
Allergic Rhinitis ◽  
Specific Immunotherapy ◽  
Serum Levels ◽  
Cytokine Level ◽  
Treatment Results ◽  
Allergen Specific Immunotherapy ◽  
Early Stages ◽  
Results Of Treatment ◽  
Long Duration ◽  
Persistent Allergic Rhinitis

Background. To study dynamics of cytokine status during early stages of allergen-specific immunotherapy (ASIT) in children suffering from persistent allergic rhinitis (PAR). Methods. 30 children suffering from PAR have received complete course of ASIT. Serum levels ofILL-4, -5, -6, -8, -12, -13, sIL-2R were studied in 0, 7, 30 and 90 days and have been analyzed differentially in groups with good/excellent and incomplete effectiveness of treatment. Results. Good/excellent effectiveness of completed course of ASIT has been demonstrated in 17/30 (56,7%) children, partial effectiveness has been demonstrated for 13/30 (43,3%) ones.The decreased IL-12 and IL-6 levels and the increase of sIL-2R production were described for good/excellent results of treatment, but insufficient effectiveness was characterized by delayed dynamics of these cytokines. IL-8 level was increased in both groups but decreased effectiveness was associated with early start and long duration of it. IL-4 production was decreased in the good/ excellent group while on the second one changes of cytokine level were absent. IL-13 and IL-5 synthesis were increased in both groups. Conclusion. The effectiveness of ASIT in PAR patients depends on synthesis dynamics of ILL-4, -6, -8, -12, sIL-2R at the early treatment stages.

Sign in / Sign up

Export Citation Format

Share Document